 Surrozen Inc NASDAQ: SRZN announced that preclinical data from its inflammatory bowel disease IBD program, SZN-1326, were presented during the 2021 United European Gastroenterology Week. Related: See Why Surrozen Stock Is Surging On Tuesday. 